Gut microbiota-generated metabolites: missing puzzles to hosts’ health, diseases, and aging

키워드

참고문헌 (92)

1. Zmora N, "You are what you eat : diet, health and the gut microbiota", Nat Rev Gastroenterol Hepatol, 16, pp.35~56 (2019)
2. Yang JY, "The gut microbiota : a key regulator of metabolic diseases", BMB Rep, 49, pp.536~541 (2016)
3. Ramakrishna BS, "Role of the gut microbiota in human nutrition and metabolism", J Gastroenterol Hepatol, 28(Suppl 4), pp.9~17 (2013)
4. Wang L, "The role of the gut microbiota in health and cardiovascular diseases", Mol Biomed, 3, pp.30~ (2022)
5. De Vadder F, "Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits", Cell, 156, pp.84~96 (2014)
6. Zarour HM, "Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade", Cell Metab, 34, pp.1903~1905 (2022)
7. Jeong K, "Human milk oligosaccharides : the novel modulator of intestinal microbiota", BMB Rep, 45, pp.433~441 (2012)
8. Zhai S, "Dietary butyrate suppresses inflammation through modulating gut microbiota in high-fat diet-fed mice", FEMS Microbiol Lett, 366, pp.fnz153~ (2019)
9. Clifford MN, "Metabolism of phenolics in coffee and plant-based foods by canonical pathways : an assessment of the role of fatty acid beta-oxidation to generate biologically-active and-inactive intermediates", Crit Rev Food Sci Nutr, 64, pp.3326~3383 (2022)
10. Cryan JF, "The microbiota-gut-brain axis", Physiol Rev, 99, pp.1877~2013 (2019)
11. Rutsch A, "The gut-brain axis : how microbiota and host inflammasome influence brain physiology and pathology", Front Immunol, 11, pp.604179~ (2020)
12. Lavelle A, "Gut microbiota-derived metabolites as key actors in inflammatory bowel disease", Nat Rev Gastroenterol Hepatol, 17, pp.223~237 (2020)
13. Franzosa EA, "Gut microbiome structure and metabolic activity in inflammatory bowel disease", Nat Microbiol, 4, pp.293~305 (2019)
14. Dong LN, "Role of intestinal microbiota and metabolites in inflammatory bowel disease", Chin Med J(Engl), 132, pp.1610~1614 (2019)
15. Cuevas-Sierra A, "Diet, gut microbiota, and obesity : links with host genetics and epigenetics and potential applications", Adv Nutr, 10, pp.S17~S30 (2019)
16. Ryu D, "Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents", Nat Med, 22, pp.879~888 (2016)
17. D’Amico D, "Impact of the natural compound Urolithin A on health, disease, and aging", Trends Mol Med, 27, pp.687~699 (2021)
18. Um JH, "Emerging role of mitophagy in human diseases and physiology", BMB Rep, 50, pp.299~307 (2017)
19. Park W, "Diversity and complexity of cell death : a historical review", Exp Mol Med, 55, pp.1573~1594 (2023)
20. Drummond MJ, "Downregulation of E3 ubiquitin ligases and mitophagy-related genes in skeletal muscle of physically inactive, frail older women : a cross-sectional comparison", J Gerontol A Biol Sci Med Sci, 69, pp.1040~1048 (2014)
21. Liu S, "Effect of Urolithin A supplementation on muscle endurance and mitochondrial health in older adults : a randomized clinical trial", JAMA Netw Open, 5, pp.e2144279~ (2022)
22. Singh A, "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults", Cell Rep Med, 3, pp.100633~ (2022)
23. Dao T, "Sarcopenia and muscle aging : a brief overview", Endocrinol Metab(Seoul), 35, pp.716~732 (2020)
24. Andreux PA, "The mitophagy activator Urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans", Nat Metab, 1, pp.595~603 (2019)
25. Nguyen TT, "Mitochondria-associated programmed cell death as a therapeutic target for age-related disease", Exp Mol Med, 55, pp.1595~1619 (2023)
26. Oh CM, "Mitochondrial quality control in the heart : new drug targets for cardiovascular disease", Korean Circ J, 50, pp.395~405 (2020)
27. Savi M, "In vivo administration of Urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats", Cardiovasc Diabetol, 16, pp.80~ (2017)
28. Gattinoni L, "T memory stem cells in health and disease", Nat Med, 23, pp.18~27 (2017)
29. Denk D, "Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy", Immunity, 55, pp.2059~2073 (2022)
30. Casedas G, "The metabolite Urolithin-A ameliorates oxidative stress in neuro-2a cells, becoming a potential neuroprotective agent", Antioxidants(Basel), 9, pp.177~ (2020)
31. Wu Y, "Dietary intervention with the gut microbial metabolite Urolithin A attenuates lipopolysaccharide-induced neuroinflammation and cognitive deficits via the sirt1", acetyl-NF-kappaB signaling pathway, 2023, pp.67, e2200401~
32. Qiu J, "Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson’s disease model", Neuropharmacology, 207, pp.108963~ (2022)
33. Gong Z, "Urolithin A attenuates memory impairment and neuroinflammation in APP", PS1mice, 2019, pp.16, 62~
34. Cho SI, "Urolithin A attenuates auditory cell senescence by activating mitophagy", Sci Rep, 12, pp.7704~ (2022)
35. Fonseca E, "Anti-aging effect of Urolithin-A on bovine oocytes in vitro", Animals(Basel), 11, pp.2048~ (2021)
36. Zhang W, "Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-alpha-dependent gene expression", Mol Nutr Food Res, 60, pp.2387~2395 (2016)
37. Setchell KD, "Equol : pharmacokinetics and biological actions", J Nutr, 140, pp.S1363~S1368 (2010)
38. Sekikawa A, "Effect of S-equol and soy isoflavones on heart and brain", Curr Cardiol Rev, 15, pp.114~135 (2019)
39. Lephart ED, "Skin aging and oxidative stress : equol’s anti-aging effects via biochemical and molecular mecha-nisms", Ageing Res Rev, 31, pp.36~54 (2016)
40. Nishimura Y, "S-equol exerts estradiol-like anorectic action with minimal stimulation of estrogen receptor-alpha in ovariectomized rats", Front Endocrinol(Lausanne), 8, pp.281~ (2017)
41. Lu Z, "S-equol, a secondary metabolite of natural anticancer isoflavone daidzein, inhibits prostate cancer growth in vitro and in vivo, though activating the Akt", FOXO3a pathway, 2016, pp.16, 455~465
42. Johnson SL, "Equol, a blood-brain barrier permeable gut microbial metabolite of dietary isoflavone daidzein, exhibits neuroprotective effects against neurotoxins induced toxicity in human neuroblastoma SH-SY5Y cells and caenorhabditis elegans", Plant Foods Hum Nutr, 75, pp.512~517 (2020)
43. Zuo LS, "Isoflavone biomarkers are inversely associated with atherosclerosis progression in adults : a prospective study", Am J Clin Nutr, 114, pp.203~213 (2021)
44. Chuang HL, "Circulating gut microbiota-related metabolites influence endothelium plaque lesion formation in ApoE knockout rats", PLoS One, 17, pp.e0264934~ (2022)
45. Takeda T, "Evaluation of a natural S-equol supplement in treating premenstrual symptoms and the effect of the gut microbiota : an open-label pilot study", Neuropsychopharmacol Rep, 42, pp.127~134 (2022)
46. Blake C, "Neuromodulation by soy diets or equol : antidepressive & anti-obesity-like influences, age-& hormonedependent effects", BMC Neurosci, 12, pp.28~ (2011)
47. Bax EN, "Opposing effects of S-equol supplementation on metabolic and behavioral parameters in mice fed a high-fat diet", Nutr Res, 64, pp.39~48 (2019)
48. Johnson SL, "Polyphenol microbial metabolites exhibit gut and blood-brain barrier permeability and protect murine microglia against LPS-induced inflammation", Metabolites, 9, pp.78~ (2019)
49. Yang F, "Urinary phytoestrogens and the risk of uterine leiomyomata in US women", BMC Womens Health, 23, pp.261~ (2023)
50. Brown NM, "Impact of perinatal exposure to equol enantiomers on reproductive development in rodents", Reprod Toxicol, 32, pp.33~42 (2011)
51. Mahalingam S, "Equol inhibits growth, induces atresia, and inhibits steroidogenesis of mouse antral follicles in vitro", Toxicol Appl Pharmacol, 295, pp.47~55 (2016)
52. Haudum C, "Impact of short-term isoflavone intervention in polycystic ovary syndrome(PCOS)patients on microbiota composition and metagenomics", Nutrients, 12, pp.1622~ (2020)
53. Li X, "Trimethylamine-N-oxide pathway : a potential target for the treatment of MAFLD", Front Mol Biosci, 8, pp.733507~ (2021)
54. Janeiro MH, "Implication of trimethylamine N-oxide(TMAO)in disease : potential biomarker or new therapeutic target", Nutrients, 10, pp.1398~ (2018)
55. Treberg JR, "Elevated levels of trimethylamine oxide in deep-sea fish : evidence for synthesis and intertissue physiological importance", J Exp Zool, 293, pp.39~45 (2002)
56. Geng J, "Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK", JNK pathway, 2018, pp.97, 941~947
57. Arrona Cardoza P, "Alzheimer’s disease and gut microbiota : does trimethylamine N-oxide(TMAO)play a role?", Nutr Rev, 80, pp.271~281 (2022)
58. Buawangpong N, "The role of trimethylamine-N-oxide in the development of Alzheimer’s disease", J Cell Physiol, 237, pp.1661~1685 (2022)
59. Schugar RC, "The TMAOproducing enzyme flavin-containing monooxygenase 3regulates obesity and the beiging of white adipose tissue", Cell Rep, 19, pp.2451~2461 (2017)
60. Chen S, "Trimethylamine N-oxide binds and activates perk to promote metabolic dysfunction", Cell Metab, 30, pp.1141~1151 (2019)
61. Annunziata G, "Polycystic ovary syndrome and cardiovascular risk. Could trimethylamine N-oxide(TMAO)be a major player? A potential upgrade forward in the DOGMA theory", Biomed Pharmacother, 143, pp.112171~ (2021)
62. Eyupoglu ND, "Circulating gut microbiota metabolite trimethylamine Noxide and oral contraceptive use in polycystic ovary syndrome", Clin Endocrinol(Oxf), 91, pp.810~815 (2019)
63. Wang H, "The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer", Cell Metab, 34, pp.581~594 (2022)
64. Koh A, "Microbially produced imidazole propionate impairs insulin signaling through mTORC1", Cell, 175, pp.947~961 (2018)
65. van Son J, "Plasma imidazole propionate is positively correlated with blood pressure in overweight and obese humans", Nutrients, 13, pp.2706~ (2021)
66. Lin K, "Gut and obesity", metabolic disease : focus on microbiota metabolites, 2022, pp.3, e171~
67. Wu B, "Imidazole propionate is increased in diabetes and associated with stool consistency", Diabetes Metab Syndr Obes, 15, pp.1715~1724 (2022)
68. Koh A, "Microbial imidazole propionate affects responses to metformin through p38gamma-dependent inhibitory AMPK phosphorylation", Cell Metab, 32, pp.643~653 (2020)
69. Molinaro A, "Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology", Nat Commun, 11, pp.5881~ (2020)
70. Molinaro A, "Microbially produced imidazole propionate is associated with heart failure and mortality", JACC Heart Fail, 11, pp.810~821 (2023)
71. Hua S, "Microbial metabolites in chronic heart failure and its common comorbidities", EMBO Mol Med, 15, pp.e16928~ (2023)
72. Raju SC, "Microbialderived imidazole propionate links the heart failure-associated microbiome alterations to disease severity", Genome Med, 16, pp.27~ (2024)
73. Kim BR, "Application of periostin peptide-decorated self-assembled protein cage nanoparticles for therapeutic angiogenesis", BMB Rep, 55, pp.175~180 (2022)
74. Ye M, "NAD(H)-loaded nanoparticles for efficient sepsis therapy via modulating immune and vascular homeostasis", Nat Nanotechnol, 17, pp.880~890 (2022)
75. Zou D, "Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI", Am J Physiol Renal Physiol, 317, pp.F1255~F1264 (2019)
76. Nguyen TT, "Local release of NECA(5’-(N-ethylcarboxamido)adenosine)from implantable polymeric sheets for enhanced islet revascularization in extrahepatic transplantation site", J Control Release, 321, pp.509~518 (2020)
77. Liu ZM, "Research protocol : effect of natural S-equol on blood pressure and vascular function--a six-month randomized controlled trial among equol non-producers of postmenopausal women with prehypertension or untreated stage 1 hypertension", BMC Complement Altern Med, 16, pp.89~ (2016)
78. Constantino-Jonapa LA, "Contribution of trimethylamine N-oxide(TMAO)to chronic inflammatory and degenerative diseases", Biomedicines, 11, pp.431~ (2023)
79. Tang WHW, "Plasma trimethylamine N-oxide(TMAO)levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study", Am Heart J, 236, pp.80~86 (2021)
80. Brunt VE, "Gut microbiome-derived metabolite trimethylamine N-oxide induces aortic stiffening and increases systolic blood pressure with aging in mice and humans", Hypertension, 78, pp.499~511 (2021)
81. Xiong X, "The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy", Lipids Health Dis, 21, pp.60~ (2022)
82. Barrea L, "Trimethylamine-N-oxide(TMAO)as novel potential biomarker of early predictors of metabolic syndrome", Nutrients, 10, pp.1971~ (2018)
83. Lemaitre RN, "Association of trimethylamine N-oxide and related metabolites in plasma and incident type 2 diabetes : the cardiovascular health study", JAMA Netw Open, 4, pp.e2122844~ (2021)
84. Gao J, "Gut microbial taxa as potential predictive biomarkers for acute coronary syndrome and post-STEMI cardiovascular events", Sci Rep, 10, pp.2639~ (2020)
85. Zhou X, "Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction", ESC Heart Fail, 7, pp.188~193 (2020)
86. Tang WH, "Gut microbiota-dependent trimethylamine N-oxide(TMAO)pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease", Circ Res, 116, pp.448~455 (2015)
87. Wang Z, "Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection", Microbiome, 11, pp.119~ (2023)
88. Troseid M, "Gut Microbiota alterations and circulating imidazole propionate levels are associated with obstructive coronary artery disease in people with HIV", J Infect Dis, 229, pp.898~907 (2024)
89. Jeong SM, "The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model", BMB Rep, 56, pp.404~409 (2023)
90. Park SJ, "PD-1 deficiency protects experimental colitis via alteration of gut microbiota", BMB Rep, 50, pp.578~583 (2017)
91. Park H, "Scarring the early-life microbiome : its potential life-long effects on human health and diseases", BMB Rep, 56, pp.469~481 (2023)
92. Lo Sasso G, "Loss of Sirt1 function improves intestinal anti-bacterial defense and protects from colitis-induced colorectal cancer", PLoS One, 9, pp.e102495~ (2014)

관련 논문AI추천